MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data
Executive Overview In a significant development for the global oncology landscape, pharmaceutical giants MSD (known as Merck & Co. in...
Executive Overview In a significant development for the global oncology landscape, pharmaceutical giants MSD (known as Merck & Co. in...
Executive Overview In a monumental step forward for global health security, biotechnology pioneer Moderna has officially dosed its first participants...
Executive Overview In a significant milestone for modern oncology and targeted drug delivery, biopharmaceutical innovator SystImmune has officially dosed the...
Executive Overview In the high-stakes arena of modern oncology, time is the ultimate currency. For brain cancer patients navigating the...